(HealthDay) -- For children with Hodgkin's lymphoma who respond to chemotherapy, treatment with low-dose involved-field radiation therapy (IFRT) improves event-free survival (EFS), but has no significant impact on overall ...
May 31, 2012
0
0
UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.
Oct 18, 2012
0
0
A University of Queensland researcher has found patients with non-hodgkins lymphoma are most likely to survive if they have a rich variety of T-cells.
Apr 3, 2017
0
51
A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into ...
Dec 10, 2023
0
15
(Medical Xpress)—Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study ...
Oct 10, 2012
0
0
Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...
Nov 26, 2014
0
0
Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) that comes in three different variants: endemic, immunodeficiency-associated, and sporadic. Of these variants, sporadic BL is most commonly found ...
Sep 1, 2021
0
4
Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.
Mar 19, 2021
0
2
Adult patients with a type of cancer known as Burkitt lymphoma had excellent long-term survival rates—upwards of 90 percent—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial ...
Nov 13, 2013
0
1
Among patients with lymphoma admitted to the hospital for severe COVID-19, those treated with B-cell-depleting therapies within the previous 12 months had an increased risk of prolonged hospital stay and death, according ...
Feb 4, 2021
0
3
